60-day mortality and the role of SARS-CoV-2 in hospital admissions of immunocompromised patients during later Omicron period: a population-based study in Sweden
2025 (English)In: Infectious Diseases, ISSN 2374-4235, E-ISSN 2374-4243, Vol. 57, no 6, p. 561-573Article in journal (Refereed) Published
Abstract [en]
BackgroundReal-world data on hospitalised SARS-CoV-2-positive patients are important for post-pandemic preventive measures.ObjectivesThis study aims to explore 60-day mortality of immunocompromised patients hospitalised in later Omicron period, accounting for the relevance of COVID-19 for hospital care.MethodsA retrospective population-based cohort study in & Ouml;sterg & ouml;tland County, Sweden, included all adult patients with a positive SARS-CoV-2 PCR test within 3 weeks of hospital admission. Clinical data including functional level (combined assessment of frailty and performance status), and COVID-19's impact on hospital care were collected from medical records. An adjusted binary logistic regression model was applied for the main outcome of 60-day COVID-19-related mortality, with immunosuppression as the main exposure.Results1128 hospitalised SARS-CoV-2-positive patients were included in the analysis whereof 12.9% were immunocompromised. Hospital admission due to COVID-19 was significantly more common among immunocompromised than non-immunocompromised (71.9% vs 49.5%), and 60-day COVID-19 mortality was 10.5% and 8.0% (p = 0.41), respectively. The median age of patients hospitalised due to COVID-19 was 78 years, with most having low/very low functional levels and >= 3 comorbidities. Adjusted for possible confounders, immunosuppression showed a significantly increased risk of 60-day COVID-19-related mortality (OR 2.41, 95% CI 1.06-5.47, p = 0.04).ConclusionA majority of COVID-19-related hospitalisations during later Omicron period in a high immunity population, involved people over 70 years with low/very low functional levels and multiple comorbidities. Immunocompromised patients had a 2.5 times higher risk of 60-day COVID-19-related mortality. These findings underscore the need for targeted preventive measures in vulnerable elderly and immunocompromised populations to mitigate COVID-19-related hospitalisations and deaths.
Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD , 2025. Vol. 57, no 6, p. 561-573
Keywords [en]
SARS-CoV-2; Omicron; mortality; immunocompromised; frailty; performance status
National Category
Surgery
Identifiers
URN: urn:nbn:se:liu:diva-212027DOI: 10.1080/23744235.2025.2465828ISI: 001422821700001PubMedID: 39955754Scopus ID: 2-s2.0-85218190179OAI: oai:DiVA.org:liu-212027DiVA, id: diva2:1942436
Note
Funding Agencies|Swedish Research Council [VR 2021-05608]; Region Ostergotland [ALF-936190]; Research Council of Southeast Sweden [FORSS-940915]; Swedish Heart-Lung Foundation [20220238]
2025-03-052025-03-052026-03-31Bibliographically approved